Anticancer Research, 31(2), 607-611
Studies indicate that intake of vitamin D in the range from 1,100 to 4,000 IU/d and a serum 25-hydroxyvitamin D concentration [25(OH)D] from 60-80 ng/ml may be needed to reduce cancer risk. Few community-based studies allow estimation of the dose-response relationship between oral intake of vitamin D and corresponding serum 25(OH)D in the range above 1,000 IU/d.
A descriptive study of serum 25(OH)D concentration and self-reported vitamin D intake in a community-based cohort (n = 3,667, mean age 51.3 ± 13.4 y).
Serum 25(OH)D rose as a function of self-reported vitamin D supplement ingestion in a curvilinear fashion, with no intakes of 10,000 IU/d or lower producing 25(OH)D values above the lower-bound of the zone of potential toxicity (200 ng/ml). Unsupplemented all-source input was estimated at 3,300 IU/d. The supplemental dose ensuring that 97.5% of this population achieved a serum 25(OH)D of at least 40 ng/ml was 9,600 IU/d.
Universal intake of up to 40,000 IU vitamin D per day is unlikely to result in vitamin D toxicity.
Garland, C. F., French, C. B., Baggerly, L. L., & Heaney, R. P. (2011). Vitamin D supplement doses and serum 25-hydroxyvitamin D in the range associated with cancer prevention. *Anticancer research*, *31*(2), 607-611. https://doi.org/10.21873/anticanres.3509
Garland CF, French CB, Baggerly LL, Heaney RP. Vitamin D supplement doses and serum 25-hydroxyvitamin D in the range associated with cancer prevention. Anticancer Res. 2011;31(2):607-611. doi:10.21873/anticanres.3509
Garland, C. F., et al. "Vitamin D supplement doses and serum 25-hydroxyvitamin D in the range associated with cancer prevention." *Anticancer research*, vol. 31, no. 2, 2011, pp. 607-611.
Cohort Studies, Dietary Supplements, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Neoplasms/blood/prevention & Control, Self Report, Vitamin D/administration & Dosage/adverse Effects/analogs & Derivatives/blood, Vitamin D, 25-hydroxyvitamin D